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J.J.J.v.L., J.L.v.P.), University of Groningen and University Medical Center Groningen, 9700 RB
Groningen, The Netherlands; and Department of Cell Biology and Genetics (A.v.T.), Erasmus University
Medical Center, 3015 CE Rotterdam, The Netherlands
Context: Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) predicts incident cardiovascu-
lar disease and is associated preferentially with negatively charged apolipoprotein B-containing
lipoproteins. The plasma cholesteryl ester transfer (CET) process, which contributes to low high-
density lipoprotein cholesterol and small, dense low-density lipoproteins, is affected by the com-
position and concentrationof apolipoproteinB-containing cholesteryl ester acceptor lipoproteins.
Objective: We tested relationships of CET with Lp-PLA2 in subjects with and without metabolic
syndrome (MetS).
Design and Setting: In 68 subjects with MetS and 74 subjects without MetS, plasma Lp-PLA2 mass,
cholesterol esterification (EST), lecithin:cholesterol acyltransferase (LCAT) activity level, CET, CET
protein (CETP) mass, and lipoproteins were measured.
Results: EST, LCATactivity, CET (P 0.001 for all), andCETP (P 0.030)were increased, and Lp-PLA2
was decreased (P 0.043) inMetS. CETwas correlated positively with Lp-PLA2 in subjects with and
without MetS (P  0.05 for both). EST and LCAT activity were unrelated to Lp-PLA2, despite a
positive correlation between EST and CET (P 0.001). After controlling for age, sex, and diabetes
status, CET was determined by Lp-PLA2 in the whole group ( 0.245; P 0.001), and in subjects
with ( 0.304; P 0.001) and without MetS ( 0.244; P 0.006) separately, independently of
triglycerides and CETP.
Conclusions:PlasmaCET is related toLp-PLA2 in subjectswithandwithoutMetS. TheprocessofCET,
but not EST,may be influenced by Lp-PLA2. These findings provide a rationale to evaluatewhether
maneuvers that inhibit Lp-PLA2 will reduce CET, and vice versa to document effects of CETP inhi-
bition on Lp-PLA2. (J Clin Endocrinol Metab 96: 1077–1084, 2011)
Lipoprotein-associated phospholipase A2 (Lp-PLA2;platelet-activating factor acetylhydrolase) is a calcium-
independent phospholipase that is secreted by macro-
phages and other inflammatory cells in the vessel wall
(1–4). In human plasma, Lp-PLA2 is bound to apolipo-
protein (apo) B-containing lipoproteins and to some ex-
tent also to high-density lipoprotein (HDL) (1–4). Well-
characterized activities of Lp-PLA2 include its ability to
hydrolyze low-density lipoprotein (LDL)-derived oxi-
dized phospholipids and long acyl chain phospholipid hy-
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droperoxides, which results in the generation of proin-
flammatory oxidized nonesterified fatty acids, fatty acid
hydroperoxides, and lysophospholipids (1–3, 5, 6). The
potential pathogenic role of Lp-PLA2 in cardiovascular
disease development has received much attention in the
past few years (1–3). A recent meta-analysis, comprising
previously published and unpublished data from more
than 79,000 individuals, has unequivocally demonstrated
independent positive relationships between plasma Lp-
PLA2 mass and activity levels and incident cardiovascular
disease (7).
Despite growing interest in the role of Lp-PLA2 in
atherogenesis, its possible effects on lipoprotein metabo-
lism are largely unknown. The process of cholesteryl ester
transfer (CET), mediated by CET protein (CETP), repre-
sents an important pathwaywhereby cholesteryl esters are
transported fromHDL toward apo B-containing lipopro-
teins (8–12). Plasma CET will decrease cholesterol in
HDL particles and increase the cholesterol content in apo
B-containing lipoproteins, as well as contribute to the for-
mation of small, dense LDL. This provides a rationale for
the development of novel drugs that inhibit CETP (11–
14). Importantly, the rate of CET toward apo B-contain-
ing acceptor lipoproteins is affected by their size, protein
content, and lipid composition (8, 9, 15–17). In this re-
gard, it is relevant that theCETprocess is also governedby
the charge characteristics of the acceptor lipoproteins, in
such away that negatively charged particles preferentially
accept cholesteryl esters (16, 18). This may explain why
CET is enhanced upon association of nonesterified fatty
acids with cholesteryl ester acceptor lipoproteins (19). In
turn, several reports indicate thatLp-PLA2associatespref-
erentially with negatively charged apo B-lipoproteins, in-
cluding small, dense LDL (3, 20, 21). Therefore, it is plau-
sible to hypothesize that the plasma Lp-PLA2 level is a
determinant of CET.
Thepresent studywas carriedout todeterminewhether
plasma CET is related to Lp-PLA2, independently of
plasma lipoproteins. Enhanced CET has been shown in
subjects with the metabolic syndrome (MetS) (22) and
accordingly in insulin-resistant individuals (23).We there-
fore decided to study relationships of plasma CET with
Lp-PLA2 in subjects with and without MetS. Second, be-
cause plasmaCET and cholesterol esterification (EST) are
thought to be coordinately regulated processes (24–26),
we also evaluated relationships of plasma EST with
Lp-PLA2.
Subjects and Methods
The protocol was approved by the medical ethics committee of
theUniversityMedicalCenterGroningen, TheNetherlands. The
participants (aged 18 yr) were recruited by advertisement in
local newspapers and provided written informed consent. Phys-
ical examination did not reveal pulmonary or cardiac abnormal-
ities. Clinically manifest cardiovascular disease, renal insuffi-
ciency, thyroid disorders, liver diseases, current pregnancy,
smoking, consumption of more than three alcoholic drinks per
day, and statin therapy were exclusion criteria. The use of an-
tihypertensive drugs was allowed. Subjects with type 2 dia-
betes mellitus (previously diagnosed by primary care physi-
cians using glucose cutoff values as defined by the World
Health Organization) were not excluded, except when using
insulin or thiazolidinediones.
Body mass index (BMI) was calculated as weight divided by
height squared (in kilograms/meter2). Waist circumference was
measured between the 10th rib and the iliac crests. Systolic and
diastolic blood pressure was measured in a sitting position with
a sphygmomanometer after a 15-min rest.All subjectswere stud-
ied after an overnight fast.
MetS was defined according to the revised National Choles-
terol Education ProgramAdult Treatment Panel III criteria (27).
Three or more of the following criteria were required for cate-
gorizationof subjectswithMetS:waist circumference larger than
102 cm for men and larger than 88 cm for women; hypertension
(blood pressure 130/85 mm Hg or use of antihypertensive
drugs); fasting plasma triglycerides of at least 1.7 mmol/liter;
HDL cholesterol below 1.0 mmol/liter for men and below 1.3
mmol/liter for women; and fasting glucose of at least 5.6 mmol/
liter or known diabetes.
Laboratory analyses
Venous blood samples were collected into EDTA-containing
tubes (1.5 mg/ml). Samples were prepared by centrifugation at
1400 g for 15 min at 4 C. Glucose was measured shortly after
blood collection. Samples for other assays were kept frozen at
80 C until assay.
Cholesterol and triglycerides were assayed by routine enzy-
matic methods (Roche/Hitachi catalog nos. 11875540 and
11876023, respectively; Roche Diagnostics GmbH,Mannheim,
Germany). HDL cholesterol wasmeasuredwith a homogeneous
enzymatic colorimetric test (Roche/Hitachi catalog no.
04713214; Roche Diagnostics GmbH). Non-HDL cholesterol
was calculated as the difference between total cholesterol and
HDL cholesterol. Apo B was assayed by immunoturbidimetry
(Roche/Cobas IntegraTinaquant catalogno. 030332574;Roche
Diagnostics GmbH).
Plasma CET was assayed by a radioisotope method as de-
scribed previously (26, 28). In short, [3H]cholesterol was equil-
ibrated for 24 h with plasma cholesterol at 4 C, followed by
incubation at 37 C for 3 h. Apo B-containing lipoproteins were
then precipitated by the addition of phosphotungstate/MgCl2.
Lipids were extracted from the precipitate, and the labeled cho-
lesteryl esters were separated from labeled unesterified choles-
terol on silica columns. This isotope method is an accurate mea-
sure of net mass transfer of cholesteryl esters from HDL to apo
B-containing lipoproteins (29). Plasma EST in total plasma was
measured as the generation of cholesteryl esters after addition of
[3H]cholesterol to plasma according to a previously described
procedure (26, 28). EST was assayed using the same incubation
system as for the CET assay. The EST rate is linear with time for
5 h, indicating an excess of unesterified cholesterol in the assay
system. All assays were performed in duplicate. The CET and
ESTmeasurements are expressed in nanomoles per milliliter per
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hour. The within-assay coefficients of variation of plasma CET
and EST are less than 7.5%.
Plasma CETP mass was measured with a double-antibody
sandwich ELISA (courtesy of Dr. G. M. Dallinga-Thie, Amster-
dam, The Netherlands) (30). A combination of monoclonal an-
tibodies TP1 and TP2 was employed as coating antibodies, and
monoclonal antibody TP20, labeled with digoxigenine, was the
secondary antibody. The CETP control samples were validated
using a RIA (carried out by Dr. R. M. McPherson, Montreal,
Canada). The plasma CETP concentration is closely correlated
with CETP activity level measured using an excess exogenous
substrate assay (31). Plasma lecithin:cholesterol acyltransferase
(LCAT) activity level was determined using excess exogenous
substrate containing [3H]cholesterol (32–34). In brief, plasma
samples were incubated with labeled substrate for 6 h at 37 C.
The reaction was stopped by addition of cold ethanol to the
incubation medium. Free and esterified cholesterol were sepa-
rated using silica columns. [3H]cholesteryl esters were eluted
with hexane. In this assay, LCAT activity varies linearly with the
amount of plasma in the incubations. LCAT activity measured
usinga comparable exogenous substratemethodhasbeen shown
to be strongly correlated with its concentration in plasma (35,
36). LCATactivitywas related to the activitymeasured inhuman
pool plasma and was expressed in arbitrary units (AU; corre-
sponding to the percentage of the activity in human pool plasma;
100 AU is equivalent to 87 nmol cholesterol esterified per ml of
plasma per hour). CETPmass and LCATactivityweremeasured
in duplicate, and their intraassay coefficients of variation are less
than 5.0%.
Lp-PLA2 mass was assayed using a commercially turbidime-
tric immunoassay (PLAC Test, diaDexus catalog no. 10-0112;
diaDexus Inc., San Francisco, CA) on the Modular P. The man-
ufacturer’s instructions for thawing samples were strictly fol-
lowed. In samples with ameasured concentration exceeding 360
g/liter, the presence of interfering heterophilic antibodies was
excluded. The intraassay coefficient of variation was 1.7%, us-
ing the EP5 protocol (Evaluation of Precision Performance of
Quantitative Measurement Methods) and buffered quality con-




Dataare givenasmean SDor asmedian (interquartile range)
and were compared by unpaired t tests. Because of skewed dis-
tribution, logarithmically transformed values for triglycerides
were used. Differences in proportions of variables were deter-
mined by 2 analysis. Univariate correlations were calculated
using linear regression analysis using Pearson’s correlation co-
efficients.Multiple linear regression analysiswas performed to
disclose independent contributions of variables. Interactions
were assessed in additional analyses. To this end, the group
mean value of the continuous variable of interest was sub-
tracted from the measured value to obtain a distribution cen-
tered on the mean. Product terms between the variables of
interest were then calculated. Two-sided P values0.05 were
considered significant. For interaction terms, the level of sig-
nificance was taken at P  0.10.
Results
The study population consisted of 142 Caucasian sub-
jects, of whom 68 fulfilled the criteria for MetS (Table 1).
SubjectswithMetS tended to be older, but sex distribution
was not different between subjects with and without
MetS. Twenty-five of theMetS subjects (37%) and five of
the subjects withoutMetS (7%) were on antihypertensive
medication (P  0.001) (mostly angiotensin-converting
enzyme inhibitors, angiotensin II antagonists, diuretics,
and beta-blockers). Type 2 diabetes mellitus was more
TABLE 1. Clinical characteristics, glucose, plasma lipids and lipoproteins, EST, CET, LCAT activity level, CETP




(n  74) P value
P value adjusted
for age and sex
Age (yr) 58  9 55  10 0.051
Sex (M/F) 37/31 42/32 0.91
Type 2 diabetes mellitus (n) 52 23 0.001
Systolic blood pressure (mm Hg) 145  19 132  21 0.001 0.001
Diastolic blood pressure (mm Hg) 89  9 81  10 0.001 0.001
BMI (kg/m2) 29.8  4.4 25.1  3.3 0.001 0.001
Waist circumference (cm) 104  13 86  11 0.001 0.001
Glucose (mmol/liter) 8.6  2.6 6.2  1.5 0.001 0.001
Total cholesterol (mmol/liter) 5.59  1.02 5.49  0.92 0.54 0.58
Non-HDL cholesterol (mmol/liter) 4.40  1.02 3.95  0.96 0.008 0.007
HDL cholesterol (mmol/liter) 1.19  0.34 1.54  0.38 0.001 0.001
Triglycerides (mmol/liter) 1.94 (1.66–2.49) 1.12 (0.79–1.46) 0.001 0.001
Apo B (g/liter) 1.00  0.23 0.89  0.21 0.004 0.004
EST (nmol/ml  h) 66.8  17.2 52.6  13.9 0.001 0.001
CET (nmol/ml  h) 25.7  8.6 19.3  6.3 0.001 0.001
CETP mass (mg/liter) 2.52  0.94 2.21  0.70 0.030 0.034
LCAT activity (AU) 117  15 105  15 0.001 0.001
Lp-PLA2 (g/liter) 290  65 313  73 0.048 0.043
Data are expressed as mean  SD or median (interquartile range). M, Male; F, female.
J Clin Endocrinol Metab, April 2011, 96(4):1077–1084 jcem.endojournals.org 1079
Downloaded from https://academic.oup.com/jcem/article-abstract/96/4/1077/2720857/Plasma-Cholesteryl-Ester-Transfer-But-Not
by University of Groningen user
on 20 October 2017
prevalent among subjects with MetS (76%) compared
with subjects without MetS (31%; P  0.001; Table 1).
Oral hypoglycemic drugs (sulfonylurea and metformin,
either alone or in combination; other hypoglycemic drugs
were not used) were used by 39 (57%) of the subjects with
MetS and 15 (20%) of the subjects without MetS (P 
0.001).
As shown in Table 1, blood pressure, BMI, waist cir-
cumference, and plasma glucose were higher in subjects
with MetS than in subjects without MetS. Triglycerides,
non-HDL cholesterol, and apo B levels were also in-
creased,whereasHDLwasdecreased inMetS subjects.All
these differences remained significant after age and sex
adjustment. Plasma EST and CETwere increased inMetS
subjects, coinciding with higher LCAT activity levels and
CETPmass (Table 1). PlasmaLp-PLA2 concentrationwas
on average 7% lower inMetS subjects, and the difference
with subjects withoutMetS remained after controlling for
age and sex. However, this difference was lost after addi-
tional adjustment for diabetes status (P  0.93).
In all subjects combined, the plasma Lp-PLA2 concen-
trationwas correlatedpositivelywith total cholesterol and
non-HDL cholesterol, but not significantly with HDL
cholesterol, triglycerides, LCAT activity levels, and CETP
mass (Table 2).Comparable correlationswere observed in
subjects with and without MetS separately (Table 2), as
well as in subjects without diabetes (data not shown).
The univariate correlations of EST with LCAT activity
levels, lipids, lipoproteins, and plasma Lp-PLA2 mass are
shown in Table 3. Plasma EST was correlated positively
with CET in all subjects combined, as well as in the sep-
arate groups of subjects with and without MetS. In all
subjects together, in subjects with and without MetS sep-
arately (Table 3), and innondiabetic subjects only (n67,
data not shown), plasma EST was correlated positively
with LCAT activity, triglycerides, and non-HDL choles-
terol, but no relationship with Lp-PLA2 was observed. In
multiple linear regression analysis, plasma ESTwas found
to be predicted independently and positively by plasma
triglycerides (  0.444; P  0.001) and LCAT activity
levels (0.341;P0.001) after controlling for age (
0.001; P  0.99), sex (  0.084; P  0.143), and
diabetes status (0.137;P0.035). This analysis again
did not show a significant contribution of the Lp-PLA2
concentration to plasma EST ( 0.037; P 0.55). Fur-
ther analysis demonstrated that the absence of a relation-
ship of Lp-PLA2 with EST ( 0.013; P 0.83) was not
confounded by the use of antihypertensive and glucose-
lowering drugs (data not shown). Additional multiple lin-
ear regression analyses in subjects with and withoutMetS
separately also revealed no independent positive relation-
ship of plasma ESTwith Lp-PLA2 ( 0.114, P 0.276;
and   0.091, P  0.310, respectively, data not
shown).
Plasma CETwas found to be correlated positively with
triglycerides and non-HDL cholesterol in all subjects to-
gether and in subjects with and without MetS separately
TABLE 2. Univariate correlations of the plasma Lp-PLA2
concentration with plasma lipids and lipoproteins, LCAT
activity level, and CETP mass in all subjects combined
(n  142) and in subjects with (n  68) and without











Total cholesterol 0.294b 0.204a 0.404b
Non-HDL cholesterol 0.292b 0.226a 0.445b
HDL cholesterol 0.030 0.070 0.151
Triglycerides 0.046 0.000 0.089
LCAT activity 0.043 0.109 0.13
CETP mass 0.064 0.007 0.203a
Pearson’s correlation coefficients are shown.
a P  0.10; b P  0.001.
TABLE 3. Univariate correlations of plasma EST and CET with LCAT activity level, CETP mass, triglycerides, non-HDL
cholesterol and plasma Lp-PLA2 concentration in all subjects combined (n  142) and in subjects with (n  68) and







EST CET EST CET EST CET
CET 0.664c 0.521c 0.718c
LCAT activity 0.673c 0.529c 0.722c
CETP mass 0.266c 0.321b 0.053
Triglycerides 0.695c 0.765c 0.596c 0.700c 0.648c 0.736c
Non-HDL cholesterol 0.432c 0.649c 0.361b 0.613c 0.412c 0.654c
Lp-PLA2 0.057 0.169
a 0.010 0.246a 0.019 0.240a
Pearson’s correlation coefficients are shown.
a P  0.05; b P  0.01; c P  0.001.
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(Table 3). In all subjects together and in subjects with
MetS, plasma CET was also positively correlated with
CETP mass. In the combined subjects and subjects
with and without MetS separately, plasma CET was cor-
related positively with Lp-PLA2 (Table 3). A comparable
trend was found in nondiabetic subjects only (n 67; r
0.187; P  0.129). Multiple linear regression analysis
demonstrated that in the combined subjects plasma CET
was independently and positively related to plasma trig-
lycerides, CETP, and Lp-PLA2 after controlling for age,
sex, and diabetes status (Table 4). A graphical presenta-
tion of the relationships of plasmaCETwith Lp-LPA2 and
triglycerides, and of CETwith Lp-LPA2 andCETPmass is
provided inFigs. 1 and2, respectively.Additionalmultiple
linear regression analyses in subjects with and without
MetS (Table 4), aswell as in subjectswithout diabetes (
0.213; P  0.025), showed similar independent relation-
ships of plasma CET with Lp-PLA2. The relationship of
CET with Lp-PLA2 remained significant ( 0.167; P
0.003) after further adjustment for non-HDL cholesterol
and apo B, as well as after controlling for the use of med-
ication (antihypertensives, sulfonylurea, and metformin)
( 0.236; P 0.001; data not shown). No interactions
of plasma Lp-PLA2 with either triglycerides (  0.019;
P 0.70) or CETPmass ( 0.001; P 0.99) on plasma
CET were observed.
Discussion
This study shows for the first time that plasma CET is
correlated positively with the Lp-PLA2 concentration in
subjects with and without MetS. This effect could not be
ascribed to a relationship between plasma LP-PLA2 and
CETPmass. Furthermore, multiple linear regression anal-
ysis revealed that this relationship remained present after
adjustment for age, sex, and diabetes status as well as for
triglycerides and apo B-containing lipoproteins, and was
independent of plasma CETP mass. These results agree
with the hypothesis that the process of CET is influenced by
TABLE 4. Multiple linear regression analyses showing relationships of plasma CET with CETP mass, triglycerides, and
Lp-PLA2 in all subjects combined (n  142), subjects with MetS (n  68), and subjects without MetS (n  74)
All subjects Subjects with MetS
Subjects without
MetS
 P value  P value  P value
Diabetes (yes/no) 0.178 0.003 0.143 0.112 0.220 0.014
Ln triglycerides 0.723 0.001 0.666 0.001 0.743 0.001
CETP mass 0.148 0.005 0.265 0.002 0.015 0.844
Lp-PLA2 0.245 0.001 0.304 0.001 0.244 0.006
All models are adjusted for age and sex.  , Standardized regression coefficient.
FIG. 1. Graphical presentation of the relationships of plasma CET with
Lp-LPA2 and triglycerides. Standardized regression coefficients (
values) from the multiple linear regression analysis model given in
Table 4 are used.
FIG. 2. Graphical presentation of the relationships of plasma CET with
Lp-LPA2 and CETP mass. Standardized regression coefficients ( values)
from the multiple linear regression analysis model given in Table 4 are
used.
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Lp-PLA2. In contrast, plasma EST was unrelated to Lp-
PLA2, despite strong interrelations between EST and CET.
Wedecided to compare subjectswithandwithoutMetS
in the expectation that plasma CET is increased in MetS
(22, 23), as confirmed in this report. Plasma CETwas not
only affected by the triglyceride concentration, as a reflec-
tion of the concentration of triglyceride-rich lipoproteins,
but to some extent also by CETPmass. Notably, the effect
of CETPmass on CETwas not significant among subjects
without MetS. This finding is consistent with the propo-
sition that CETP may become rate limiting in the CET
process in hypertriglyceridemia (37). In agreement, it was
found earlier that plasma CET is only weakly related to
CETP activity, measured using an exogenous substrate
assay that is closely correlatedwithCETPmass (25). Like-
wise, in subjects without diabetes, no independent contri-
bution of plasma CETP mass on CET was observed in
another report (17).
Of further relevance, our study showed a moderately
decreased plasma Lp-PLA2 concentration in MetS sub-
jects. Increased Lp-PLA2 concentration and activity levels
were found previously in nondiabetic subjects with MetS
(38), and an increased Lp-PLA2 concentration was found
in diabetic patients withMetS compared with those with-
out MetS (39). It is well established that there is sufficient
agreementbetween the concentrationand theactivity level
of Lp-PLA2 in plasma (7). Nonetheless, it has been shown
that MetS exerts greater effects on the Lp-PLA2 activity
level comparedwith its plasma concentration (38).Of fur-
ther interest, the recent meta-analysis revealed lower
plasma Lp-PLA2 mass but unaltered activity in diabetes
mellitus (7). In line with a decreasing effect of the diabetic
state in Lp-PLA2, the difference in its concentration be-
tween subjects with and withoutMetS was not significant
after controlling for diabetes status. Thus, the apparent
discrepancy with respect to Lp-PLA2 concentration with
other reports (38, 39) could be explained at least in part by
the considerable number of diabetic subjects in our study
population. Although measurement of Lp-PLA2 activity
could have provided additional insight in its relation with
CET,multiple linear regression analysis did reveal that the
plasma Lp-PLA2 concentration contributed to CET inde-
pendently of diabetes status. Furthermore, comparable re-
lationships of CET with the Lp-PLA2 concentration were
seen in the separate groups of subjects with and without
MetS as well as in nondiabetic subjects only. Therefore,
the conclusion is allowed that the positive and indepen-
dent relation of CET with the Lp-PLA2 concentration is
not confined to subjects withMetS and is not confounded
by the presence of type 2 diabetes mellitus.
An increasingbodyof evidence supports thenotion that
nonesterified fatty acids and lipid peroxides are accumu-
lated in electronegative LDL particles to which Lp-PLA2
associates preferentially (3, 20, 21). In turn, the CET pro-
cess is stimulated by negatively charged cholesteryl ester
acceptor lipoproteins, although a delicate balance in the
concentration and structure of various long chain nones-
terified fatty acids seems to be required for maximal stim-
ulation ofCET (16, 18, 40). Additionally, a higher affinity
ofCETP for oxidizedLDLhas beendemonstrated in vitro,
which may be attributable to the generation of negatively
charged lipids duringLDLoxidation (16, 41). Association
of CETPwith negatively charged LDLmay affect the CET
process by targeting transfer of HDL-derived cholesteryl
esters more preferentially toward LDL (9, 16). Thus, it is
likely that the composition of apo B-containing lipopro-
teins, including their charge characteristics, affect both
plasma CET and their association with Lp-PLA2 in the
same direction. It seems plausible that the independent
relationship of plasma CET with Lp-PLA2 is not merely
associative, but could imply a causal role of Lp-PLA2 in
CET regulation or vice versa. It can be anticipated that
generation of negatively charged oxidized nonesterified
fatty acids elicited by Lp-PLA2 may increase directly the
electronegativity of apo B-containing lipoproteins (3) and
hence stimulate the CET process. In this respect, it is note-
worthy that Lp-PLA2 is able to hydrolyze long acyl chain
oxidized phospholipids, thereby generating long acyl
chain oxidized nonesterified fatty acids and fatty acid hy-
droperoxides (3). Conversely, the CET process contrib-
utes to the formation of (electronegative) small, dense
LDL (8, 9, 10),whichmay preferentially bindLp-PLA2 (3,
21). Furthermore, CETP action could also promote gen-
eration of oxidized LDL in vivo (42). Accordingly, resis-
tance of LDL particles to oxidative modification has been
observed after immunological inhibition of CETP in vitro
(43). We therefore hypothesize that the relationship of
plasma CET with Lp-PLA2, as shown in this report, may
represent implication of Lp-PLA2-mediated generation of
oxidized nonesterified fatty acids in the CET process. Al-
ternatively, this relationship could imply that the CET
process could contribute to generation of oxidized lipids
rendering apo B-containing lipoprotein (subfractions)
more electronegative, which may enhance Lp-PLA2 asso-
ciation with LDL particles.
Both possibilities can be anticipated to promote the
atherogenicity of plasma lipoproteins. If Lp-PLA2 en-
hances the CET process, then the contribution of circu-
lating Lp-PLA2 to atherosclerosis susceptibility could in
part be explained by a hitherto unappreciated contribu-
tion to an unfavorable distribution of cholesterol between
HDL and apo B-containing lipoproteins (9, 10, 12, 17).
Conversely, if plasmaCET stimulates binding of Lp-PLA2
to apo B-containing lipoproteins, then this process may
1082 Dullaart et al. Cholesteryl Ester Transfer Relates to Lp-PLA2 J Clin Endocrinol Metab, April 2011, 96(4):1077–1084
Downloaded from https://academic.oup.com/jcem/article-abstract/96/4/1077/2720857/Plasma-Cholesteryl-Ester-Transfer-But-Not
by University of Groningen user
on 20 October 2017
aggravate the prooxidative and proinflammatory poten-
tial of these lipoproteins, including small, dense LDL (3,
44). Obviously, the precise mechanisms responsible for
the relationship of plasma CET with Lp-PLA2 should be
determined in future experiments. Clearly, the present
findings provide a rationale to test whether pharmacolog-
ical inhibition of Lp-PLA2 (45, 46) will selectively reduce
the plasma CET process. Furthermore, it may be relevant
to know whether CETP inhibitors, which are anticipated
to increase LDL size (12–14), affect Lp-PLA2 binding to
LDL and its prooxidant activity.
Early studies have demonstrated that EST in incubated
plasma is stimulated by cholesteryl ester acceptor lipopro-
teins (24). This mechanism explains why the plasma tri-
glyceride concentration is a determinant of EST, besides
an effect of the LCAT activity level per se (25, 26). Our
study entirely agrees with this finding (25) and reiterates
previously documented increases in plasma EST (22) and
LCAT activity (15, 47) inMetS and dyslipidemic subjects.
The observation that CET can become rate limiting for
EST (24) most likely also underlies the strong relationship
of ESTwith CET (25, 26). In this respect, it is noteworthy
that there was no positive association of plasma ESTwith
Lp-PLA2. Although HDL size and lipid compositional
characteristics affect their binding affinity for CETP (48),
there are to our knowledge no reports that demonstrate
preferential binding of CETP to electronegativeHDL par-
ticles. Moreover, only a minor proportion of Lp-PLA2 is
associated with HDL (3), even in dyslipidemic and dia-
betic plasma where Lp-PLA2 may be redistributed from
apo B-containing lipoproteins towardHDL (4). Thus, the
present report suggests that effects of Lp-PLA2 on com-
ponents of the reverse cholesterol transport pathway are
confined to CET.
In conclusion, this study has revealed robust independent
relationshipsof plasmaCET,butnotEST,with theLp-PLA2
level in subjects with and without the MetS. This finding
raises the possibility that Lp-PLA2may specifically affect the
CET process, or alternatively that CETP inhibition could
affect Lp-PLA2 activity.
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